Table 2.

Results of logistic models to distinguish patients with PCa from patients with BPH for (A) 477 patients with PCa from 300 patients with BPH, (B) 477 patients with PCa from 95 patients with BPH with multiple negative biopsies, (C) 203 patients with Gleason Scores 7–10 PCa from 300 patients with BPH.

(A) All Patients Comparing BPH vs. PCa
Model	Cutoff	AUC	Sensitivity	Specificity	PPV	NPV	OR (CI)	p-value	nBPH	nPCa
PSA	0.61	0.55	0.9	0.057	0.6	0.27	0.55 (0.29–0.999)	0.044	300	477
Age	0.52	0.59	0.92	0.19	0.64	0.6	2.71 (1.71–4.33)	8.8 × 10−6	300	477
FLNA	0.5	0.65	0.92	0.33	0.69	0.72	5.76 (3.78–8.94)	5.7 × 10−19	300	477
PSA + Age	0.53	0.59	0.9	0.21	0.64	0.57	2.38 (1.55–3.68)	3.2 × 10−5	300	477
FLNA + Age	0.49	0.66	0.9	0.32	0.68	0.67	4.36 (2.92–6.58)	1.4 × 10−14	300	477
FLNA + Age + Vol	0.5	0.75	0.9	0.45	0.72	0.74	7.36 (4.99–11)	1.4 × 10−28	300	477
(B) All Patients Undergoing Multiple Biopsies
Model	Cutoff	AUC	Sensitivity	Specificity	PPV	NPV	OR (CI)	p-value	nBPH	nPCa
PSA	0.81	0.57	0.9	0.16	0.84	0.24	1.71 (0.848–3.3)	0.1	95	477
Age	0.72	0.69	0.92	0.31	0.87	0.43	5.06 (2.81–9.07)	2.5 × 10−8	95	477
FLNA	0.72	0.83	0.92	0.62	0.92	0.61	18.8 (10.8–33.3)	1 × 10−29	95	477
PSA + Age	0.73	0.7	0.9	0.31	0.87	0.38	4.01 (2.26–7.03)	1.1 × 10−6	95	477
FLNA + Age	0.7	0.85	0.9	0.62	0.92	0.56	14.9 (8.7–25.8)	1.2 × 10−26	95	477
FLNA + Age + Vol	0.71	0.87	0.9	0.67	0.93	0.58	18.7 (10.8–33)	4.2 × 10−31	95	477
(C) All Patients Comparing BPH with PCa Gleason Score 7–10
Model	Cutoff	AUC	Sensitivity	Specificity	PPV	NPV	OR (CI)	p-value	nBPH	nPCa
PSA	0.38	0.5	0.9	0.08	0.4	0.55	0.796 (0.408–1.57)	0.52	300	203
Age	0.35	0.55	0.92	0.15	0.42	0.73	1.98 (1.07–3.8)	0.027	300	203
FLNA	0.28	0.68	0.95	0.33	0.49	0.91	9.61 (4.83–21.3)	6.8 × 10−16	300	203
PSA + Age	0.34	0.55	0.9	0.16	0.42	0.71	1.74 (0.975–3.21)	0.062	300	203
FLNA + Age	0.28	0.68	0.9	0.33	0.48	0.83	4.56 (2.67–8.12)	3.6 × 10−10	300	203
FLNA + Age + Vol	0.29	0.77	0.9	0.44	0.52	0.87	7.07 (4.17–12.5)	3.4 × 10−17	300	203